Our Pipeline

Our first-in-class adoptive cell therapies are tailored to treat diseases with high unmet medical needs with a first focus on aggressive life-threatening cancers

carla biotherapeutics background image

Hematologic Malignancies

CARLA001
Indication Blastic Plasmacytoid
Dendritic Cell Neoplasm (BPDCN)
Target CD123
Concept
Preclinical
IND Enabling
Early Clinical
Late Clinical
CARLA001
Indication Undisclosed
Target CD123
Concept
Preclinical
IND Enabling
Early Clinical
Late Clinical

Solid Tumors

CARLA002
Indications Under selection
Target Undisclosed
Concept
Preclinical
IND Enabling
Early Clinical
Late Clinical